The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps

被引：4
|
作者：
Bertucci, Francois [1 ,2 ,3 ]
Finetti, Pascal [1 ]
Mamessier, Emilie [1 ]
De Nonneville, Alexandre [1 ,2 ]
机构：
[1] Aix Marseille Univ, Paoli Calmettes Inst, Canc Res Ctr Marseille, Lab Predict Oncol,INSERM,CNRS,UMR 1068,UMR 725,Tea, Marseille, France
[2] Paoli Calmettes Inst, Dept Med Oncol, Marseille, France
[3] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguer, F-13009 Marseille, France
来源：
CANCER COMMUNICATIONS | 2023年 / 43卷 / 08期
关键词：
PALBOCICLIB;
D O I：
10.1002/cac2.12466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [31] Mammographic density and disease-free survival in [HR+,HER2-] locally advanced breast cancer
    Rojas, K.
    Flores, R.
    Flores, C.
    Pinto, J.
    Gomez, H. L.
    Castaneda, C.
    BREAST, 2015, 24 : S103 - S103
  • [32] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [33] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [34] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E. P.
    Huang, C.
    Senkus-Konefka, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R. J.
    Andre, V.
    Munoz, M.
    Antonio, B. San
    Shahir, A.
    Jimenez, M. Martin
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
  • [35] Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 4 - 5
  • [36] Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
    Goetz, M. P.
    Turner, N.
    Sasano, H.
    Arteaga, C.
    Chandarlapaty, S.
    Loi, S.
    Reis-Filho, J. S.
    Kreipe, H.
    Harbeck, N.
    Fasching, P.
    Rubenstein, C. S.
    Wijayawardana, S.
    Munoz, M.
    Litchfield, M.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S278 - S279
  • [37] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
    Andre, V.
    Harbeck, N.
    Rastogi, P.
    O'Shaughnessy, J.
    Boyle, F.
    Cortes, J.
    Rugo, H. S.
    Goetz, M. P.
    Hamilton, E.
    Huang, C. -s.
    Senkus, E.
    Tryakin, A.
    Neven, P.
    Huober, J.
    Wei, R.
    Munoz, M.
    Antonio, B. S.
    Shahir, A.
    Martin, M.
    Johnston, S.
    BREAST, 2025, 80
  • [38] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Reinisch, Mattea
    Harbeck, Nadia
    Rastogi, Priya
    O'shaughnessy, Joyce
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Hamilton, Erika
    Goetz, Matthew P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Trakin, Alexey
    Neven, Patrick
    Huober, Jens
    Ran, Wei
    Andre, Valerie
    Munoz-Fernandez, Maria
    Antonio, Belen San
    Shahir, Ashwin
    Martin, Miguel
    Johnston, Stephen
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228
  • [39] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [40] Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
    Valerio, Maria Rosaria
    Martorana, Federica
    Sano, Maria Vita
    Sambataro, Daniela
    Motta, Gianmarco
    Motta, Lucia
    Pavone, Giuliana
    Gebbia, Vittorio
    Scandurra, Giuseppa
    BIOMEDICINES, 2025, 13 (03)
12345